Сравнение

Cerebrolysin vs. Icatibant

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

96889-70-6

138614-30-9

Молекулярная масса

нет данных

1304.52 g/mol

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Cerebrolysin

Cerebrolysin is a mixture of low-molecular-weight peptides (predominantly below 10 kDa) and free amino acids obtained by enzymatic cleavage of lipid-free porcine brain proteins. The manufacturer and preclinical literature describe a neurotrophic and neuroprotective mode of action said to mimic endogenous neurotrophic factors; cell and animal models have reported effects on neuronal survival, synaptogenesis and anti-apoptotic signalling (including PI3K/Akt). Because it is a complex, incompletely characterised mixture, the precise mechanism in humans remains unclear.

Icatibant

Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Cerebrolysin	Icatibant
Австрия	Рецептурный	—
CN	Рецептурный	—
Германия	Неясно	Рецептурный
RU	Рецептурный	—
США	Не одобрено	Рецептурный

Полные записи

Frequently asked questions

What is the difference between Cerebrolysin and Icatibant?: Cerebrolysin is classified as "Исследования (прочее)", while Icatibant is classified as "Исследования (прочее)". Cerebrolysin: Cerebrolysin (FPF-1070) is not a single peptide but a porcine-brain-derived preparation of low-molecular-weight peptides and free amino acids, produced by standardised enzymatic proteolysis. It is approved in several countries (including Austria, Russia and parts of Asia) for stroke, dementia and traumatic brain injury, but is not FDA-approved in the United States and not centrally approved by the EMA. Its efficacy is contested: Cochrane systematic reviews found no convincing benefit and flagged possible harm signals. Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Cerebrolysin or Icatibant?: The highest available evidence level is "РКИ на людях" for Cerebrolysin and "РКИ на людях" for Icatibant. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Cerebrolysin and Icatibant in Germany and the United States?: Германия: Cerebrolysin — Неясно, Icatibant — Рецептурный. США: Cerebrolysin — Не одобрено, Icatibant — Рецептурный. These are factual summaries with source and review date on the individual pages.

Country

Cerebrolysin

Icatibant

Австрия

Рецептурный

—

Рецептурный

—

Германия

Неясно

Рецептурный

—

США

Не одобрено

Рецептурный

Frequently asked questions

What is the difference between Cerebrolysin and Icatibant?

Cerebrolysin is classified as "Исследования (прочее)", while Icatibant is classified as "Исследования (прочее)". Cerebrolysin: Cerebrolysin (FPF-1070) is not a single peptide but a porcine-brain-derived preparation of low-molecular-weight peptides and free amino acids, produced by standardised enzymatic proteolysis. It is approved in several countries (including Austria, Russia and parts of Asia) for stroke, dementia and traumatic brain injury, but is not FDA-approved in the United States and not centrally approved by the EMA. Its efficacy is contested: Cochrane systematic reviews found no convincing benefit and flagged possible harm signals. Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Cerebrolysin or Icatibant?

The highest available evidence level is "РКИ на людях" for Cerebrolysin and "РКИ на людях" for Icatibant. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Cerebrolysin and Icatibant in Germany and the United States?

Германия: Cerebrolysin — Неясно, Icatibant — Рецептурный. США: Cerebrolysin — Не одобрено, Icatibant — Рецептурный. These are factual summaries with source and review date on the individual pages.